

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): March 30, 2016

**Arbutus Biopharma Corporation**  
(Exact Name of Registrant as Specified in Charter)

**BRITISH COLUMBIA, CANADA**  
(State or Other Jurisdiction of  
Incorporation)

**001-34949**  
(Commission File Number)

**980597776**  
(I.R.S. Employer Identification Number)

**100-8900 Glenlyon Parkway, Burnaby, British Columbia, Canada V5J 5J8**  
(Address of Principal Executive Offices) (Zip Code)

**(604) 419-3200**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 8.01. Other Events.**

On March 30, 2016, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

Exhibit 99.1. Press release dated March 30, 2016

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Arbutus Biopharma Corporation**

Date: March 30, 2016

By: /s/ Bruce G. Cousins

Name: Bruce G. Cousins

Title: Executive Vice President and Chief Financial Officer

**Arbutus to Present Preclinical HBV Data at EASL 2016**

VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 30, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the European Association for the Study of the Liver (EASL) selection committee has accepted an abstract for presentation at the EASL 2016 annual meeting to be held April 13 - 17, 2016, in Barcelona, Spain.

“We are pleased to present data on our core protein/capsid assembly inhibitor program, which supports our strategy of attacking HBV through multiple different mechanisms of action,” said Dr. Mark J. Murray, Arbutus’ President and CEO. “Our lead HBV product candidate, ARB-1467, is in an ongoing Phase II study in chronically infected HBV patients. In addition, we are advancing our other HBV programs to support initiation of clinical combination studies in 2017.”

**Poster Presentation**

- **Title:** "In Vitro and In Vivo Antiviral Activities of AB-423 a Potent Small Molecule Inhibitor of Hepatitis B Virus Capsid Assembly"
- **Date:** Thursday, April 14, 2016
- **Abstract Number:** THU-198

**About Arbutus**

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection. Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

**Contact Information****Investors**

Adam Cutler

Senior Vice President, Corporate Affairs

Phone: 604.419.3200

Email: [acutler@arbutusbio.com](mailto:acutler@arbutusbio.com)

Helia Baradarani

Manager, Investor Relations

Phone: 604.419.3200

Email: [hbaradarani@arbutusbio.com](mailto:hbaradarani@arbutusbio.com)

**Media**

Please direct all media inquiries to: [media@arbutusbio.com](mailto:media@arbutusbio.com)